SitemapImpressumDatenschutzerklärungdeutschenglish
MHH Logo

TECHNOBEAT

 

Tools and Technologies for Breakthrough in Heart Therapies- in short TECHNOBEAT is part of the Horizon 2020 funding programme of the European Commission.

 

TECHNOBEAT is rooted in the extensive, interdisciplinary research by basic and applied scientists at the LEBAO and clinicians at the HTTG (Department of Cardiac, Thoracic, Transplantation and Vascular Surgery) on the MHH campus. Substantial recent progress in i) human induced pluripotent stem cell (hiPSC) reprogramming and tailored genetic engineering (RG Martin), ii) novel methods for hiPSC mass production in controlled bioreactors including cardiac (RG Zweigerdt) and endothelial differentiation (RG Olmer), as well as iii) animal models of heart failure and cell therapies (RGs Haverich, Cebotari, Martens) paved the way to the EU Horizon2020 funded, trans European Network TECHNOBEAT.

 

The interdisciplinary TECHNOBEAT consortium consists of renowned experts from six European countries and Israel working in the fields of cell therapy, tissue engineering, stem cell processing and clinical translation. Together we aim to provide new treatment options for patients suffering from heart failure due to the loss of heart muscle tissue following myocardial infarction (heart attack).

 

The TECHNOBEAT Consortium

 

 

 

This Project is funded by the European Union‘s Horizon 2020 research and innovation programme

under grant agreement no. 668724

 

 

 

 

News

 

 

May 2018

 

TECHNOBEAT Session at

6th Annual German Stem Cells Network Conference

19 - 21 September 2018 in Heidelberg

 

 

In its ongoing efforts to engage with the scientific community and disseminate latest findings, TECHNOBEAT hosted a workshop at this year's GSCN Conference.

 

Hosted by Robert zweigerdt (MHH) and Dirk Strunk (PMU) the session started with a special keynote by Prof. Michael Laflamme, from Toronto General Hospital Research Institute, University Health Network and Institute of Biomaterials and Biomedical Engineering, Toronto, Canada on the topic of Human Embryonic Stem Cell-Derived Cardiomyocytes Regenerate the Infarcted Pig Heart.

 

 

Following the keynote  5 talks by junior researchers from the TECHNOBEAT consortium were presented:

 

Demkes, E., University Medical Center, Utrecht, Netherlands
Increased Retention of Cardiac Cell Aggregates in a Porcine Model of Myocardial Infarction
 
Giacomelli, E., Leiden University Medical Center, Netherlands
Human Stem Cell-Derived Cardiac Fibroblasts Enhance Structural and Functional Cardiomyocyte Maturation in a Three-Dimensional Microtissue Environment
 
Halliwell, J., University of Sheffield, United Kingdom
The detection and minimisation of genetically variant stem cells in human pluripotent stem cell cultures
 

Halloin, C., Hannover Medical School, Germany
Chemically defined cardiomyogenic differentiation of human pluripotent stem cells in bioreactors
 
Peking, P., Paracelsus Medizinische Privatuniversität, Salzburg, Austria
Development of immunosuppressive iPSC-derived stromal cells for tissue regeneration

 

 

All in all the session was a gret success, with interesting discussion points raised.

 

 Image (CC) Abhijeet Rane via Flickr